{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:09:29Z","timestamp":1789600169662,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-026-06015-7","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:06:01Z","timestamp":1782731161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the intellectual landscape of malaria drug repurposing: a systematic analysis of the 51 most cited studies"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2661-0603","authenticated-orcid":false,"given":"Daniel Thakuma","family":"Tizhe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-0713","authenticated-orcid":false,"given":"Israel Ogwuche","family":"Ogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-7927","authenticated-orcid":false,"given":"Jeremiah Zaphnathpaaneah","family":"Adaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6838-8378","authenticated-orcid":false,"given":"Samson","family":"Usman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-7570","authenticated-orcid":false,"given":"Yonni Eshovo","family":"Apeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6922-0998","authenticated-orcid":false,"given":"Jacob Kwada Paghi","family":"Kwaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5019-717X","authenticated-orcid":false,"given":"Grace Sabo Nok","family":"Kia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-0644","authenticated-orcid":false,"given":"Kodjovi","family":"Sossou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"6015_CR1","volume-title":"World malaria report 2022","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. World malaria report 2022. Geneva: World Health Organization; 2022."},{"issue":"8","key":"6015_CR2","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an observational cohort study. Lancet Infect Dis. 2021;21(8):1120\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"6015_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"6015_CR4","first-page":"89","volume-title":"Repurposing existing drugs, specifically anticancer agents like methotrexate, for the treatment of tropical diseases like malaria","author":"A Nzila","year":"2012","unstructured":"Nzila A, Chibale K. Repurposing existing drugs, specifically anticancer agents like methotrexate, for the treatment of tropical diseases like malaria. Berlin Heidelberg: Springer-Verlag; 2012. p. 89."},{"issue":"1","key":"6015_CR5","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-018-05116-5","volume":"9","author":"F Cheng","year":"2018","unstructured":"Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabasi AL, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):2691.","journal-title":"Nat Commun"},{"issue":"13","key":"6015_CR6","first-page":"4321","volume":"36","author":"X Zeng","year":"2020","unstructured":"Zeng X, Zhu S, Liu X, Zhou Y, Nussinov R, Cheng F. A network-based deep learning approach to in silico drug repositioning. Bioinformatics. 2020;36(13):4321\u20138.","journal-title":"Bioinformatics"},{"issue":"10223","key":"6015_CR7","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30\u20131.","journal-title":"Lancet"},{"key":"6015_CR8","first-page":"146","volume":"4","author":"W Sun","year":"2014","unstructured":"Sun W, Sinden RE, Wirth DF. Identification of new compounds and targets for gametocytocidal drug development to block malaria transmission targeting P. falciparum gametocytes. Sci Rep. 2014;4:146.","journal-title":"Sci Rep"},{"issue":"1","key":"6015_CR9","doi-asserted-by":"crossref","first-page":"13291","DOI":"10.1038\/s41598-021-92664-4","volume":"11","author":"ND Bakary","year":"2021","unstructured":"Bakary ND, N\u2019guessan JA, Konan BH, Kone M. In-silico strategy using drug repurposing through the screening of a set of DrugBank compounds against Plasmodium falciparum. Sci Rep. 2021;11(1):13291.","journal-title":"Sci Rep"},{"issue":"18","key":"6015_CR10","first-page":"7021","volume":"39","author":"DB Costa Junior","year":"2021","unstructured":"Costa Junior DB, de Melo LF, Mouchrek Filho VE, Costa CE, Valen\u00e7a AA, Santos DC, et al. Identification of novel lead compounds for antimalarial drug resistant strains of Plasmodium falciparum via virtual screening and in vitro assay. J Biomol Struct Dyn. 2021;39(18):7021\u201333.","journal-title":"J Biomol Struct Dyn"},{"issue":"1","key":"6015_CR11","first-page":"786","volume":"8","author":"P Mee-Udorn","year":"2023","unstructured":"Mee-Udorn P, Rukseree K, Suttisintong K. Virtual screening of 2509 FDA-approved drugs against Plasmodium using AutoDock VinaXB program. ACS Omega. 2023;8(1):786\u201394.","journal-title":"ACS Omega"},{"issue":"Suppl 1","key":"6015_CR12","first-page":"33","volume":"17","author":"Y Kalantarmotamedi","year":"2018","unstructured":"Kalantarmotamedi Y, Lio P, Al-Jawad M. Identifying novel synergistic compound combinations for the treatment of drug-resistant malaria using a combined approach of transcriptional drug repositioning\/discovery and Machine Learning. Malar J. 2018;17(Suppl 1):33.","journal-title":"Malar J"},{"issue":"22","key":"6015_CR13","first-page":"19711","volume":"8","author":"JVB Borba","year":"2023","unstructured":"Borba JVB, Rodrigues JM, Rangel LM, Sampaio ES, Araya L, Rangel-Yagui CO, et al. Transcriptomics-Guided in silico drug repurposing for the identification of novel antimalarial drug candidates. ACS Omega. 2023;8(22):19711\u201322.","journal-title":"ACS Omega"},{"key":"6015_CR14","unstructured":"Reeha S, Rajkumar M, Muthu T. Deep learning approach using convolutional neural networks (CNN) to predict drug-target protein binding affinities for antimalarial drug candidates. 2024 3rd International Conference for Innovation Technology. 2024:8."},{"issue":"1","key":"6015_CR15","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/s41598-020-80722-2","volume":"11","author":"BN Diallo","year":"2021","unstructured":"Diallo BN, Traore MA, Bamba M. Computational drug repurposing with subsequent in vitro validation: Screening 796 FDA-approved drugs against 36 P. falciparum protein targets. Sci Rep. 2021;11(1):1624.","journal-title":"Sci Rep"},{"issue":"1","key":"6015_CR16","doi-asserted-by":"crossref","first-page":"e0169461","DOI":"10.1371\/journal.pone.0169461","volume":"12","author":"RM Mogire","year":"2017","unstructured":"Mogire RM, Njuguna NM, Okomo EA. Screening approved drugs to identify those with antimalarial activity by matching their known targets with similar proteins in P falciparum proteome. PLoS ONE. 2017;12(1):e0169461.","journal-title":"PLoS ONE"},{"issue":"1","key":"6015_CR17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13321-024-00856-7","volume":"16","author":"RM Mogire","year":"2024","unstructured":"Mogire RM, Okomo EA, Njuguna NM. Identifying and validating new potential anti-malarial drugs by repurposing compounds from the ReFRAME library against P. falciparum. J Cheminform. 2024;16(1):7.","journal-title":"J Cheminform"},{"issue":"3","key":"6015_CR18","first-page":"858","volume":"107","author":"R Badhan","year":"2018","unstructured":"Badhan R, Alwadei MK, Youssif M. Physiologically-based pharmacokinetic modeling to optimize the dosing regimen of ivermectin for malaria control. J Pharm Sci. 2018;107(3):858\u201365.","journal-title":"J Pharm Sci"},{"issue":"Suppl 1","key":"6015_CR19","first-page":"62","volume":"13","author":"J Lotharius","year":"2014","unstructured":"Lotharius J, Llin\u00e1s M, Gamo FJ. Drug repositioning for new antimalarial medicines against P. falciparum blood stages. Malar J. 2014;13(Suppl 1):62.","journal-title":"Malar J"},{"key":"6015_CR20","volume":"108","author":"A Das","year":"2024","unstructured":"Das A, Sharma R, Sanyal S, Bhati VS, Singh DP, Kumar R, et al. In silico drug repurposing against Plasmodium falciparum Plasmepsin V: A target identification and molecular dynamics approach. Comput Biol Chem. 2024;108:107996.","journal-title":"Comput Biol Chem"},{"issue":"1","key":"6015_CR21","first-page":"180","volume":"69","author":"SR Prabhu","year":"2024","unstructured":"Prabhu SR, Prakash RM, Aravindh S. In Silico Drug Repositioning guided by MicroRNAs (miRNAs) to predict new drug-disease relationships for antimalarials. Acta Parasitol. 2024;69(1):180\u20138.","journal-title":"Acta Parasitol"},{"key":"6015_CR22","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.crstbi.2024.100128","volume":"7","author":"A Mishra","year":"2024","unstructured":"Mishra A, Saxena S, Singh pp. Antimalarial drug discovery focusing on repurposing existing HIV-1 drugs to inhibit protease in the P falciparum parasite using X-ray Crystallography. Curr Res Struct Biol. 2024;7:100125.","journal-title":"Curr Res Struct Biol"},{"key":"6015_CR23","doi-asserted-by":"crossref","first-page":"e26703","DOI":"10.7554\/eLife.29865","volume":"6","author":"K Amberg-Johnson","year":"2017","unstructured":"Amberg-Johnson K, Hari SB, Ganesan SM, Lorenzi HA, Sauer RT, Niles JC, et al. The essential apicoplast-localized FtsH1 is a target for the antimalarial drug actinonin. Elife. 2017;6:e26703.","journal-title":"Elife"},{"issue":"2","key":"6015_CR24","first-page":"e01389","volume":"66","author":"A Chaurasiya","year":"2022","unstructured":"Chaurasiya A, Singh N, Meena RK, Jha AN. Repurposing the anti-Hepatitis C virus drug, Alisporivir, as a potent antimalarial agent against drug-resistant P. falciparum strains. Antimicrob Agents Chemother. 2022;66(2):e01389-e1421.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6015_CR25","volume":"64","author":"JG Woodland","year":"2025","unstructured":"Woodland JG, Muriuki SM, Wirth DF. Repurposing AZD0156 as a new, multistage antimalarial candidate: Validation of Plasmodium Phosphatidylinositol 4-kinase type III beta inhibition. Angew Chem Int Ed Engl. 2025;64(5):e202318456.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"6015_CR26","doi-asserted-by":"publisher","first-page":"6340","DOI":"10.1128\/AAC.00899-15","volume":"59","author":"TE Kraft","year":"2015","unstructured":"Kraft TE, Gamo FJ, Riscoe MK. The HIV protease inhibitor lopinavir targets the malarial glucose transporter PfHT1. Antimicrob Agents Chemother. 2015;59(10):6340\u20131.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"6015_CR27","first-page":"30","volume":"7","author":"NV Simwela","year":"2021","unstructured":"Simwela NV, Sridhar R, Patterton HG. Developing new treatments and overcoming drug resistance for malaria: ubiquitin-proteasome system inhibitors. ACS Infect Dis. 2021;7(1):30\u201345.","journal-title":"ACS Infect Dis"},{"issue":"6","key":"6015_CR28","first-page":"977","volume":"10","author":"EOJ Porta","year":"2019","unstructured":"Porta EOJ, da Silva JAG, de Souza EA. Repositioning cancer drug candidate Salirasib and its analogs to treat malaria by inhibiting the P. falciparum Isoprenylcysteine Carboxyl Methyltransferase. Med Chem Commun. 2019;10(6):977\u201384.","journal-title":"Med Chem Commun"},{"key":"6015_CR29","doi-asserted-by":"crossref","first-page":"100523","DOI":"10.1016\/j.ijpddr.2024.100523","volume":"24","author":"F Olotu","year":"2024","unstructured":"Olotu F, Ogunsola M, Olomu I. Identifying and validating a compound to be a multi-stage pan-inhibitor against a class of targets (class 1a aminoacyl tRNA synthetases) in the malaria parasite, P. falciparum. Int J Parasitol Drugs Drug Resist. 2024;24:100523.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"6015_CR30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fchem.2019.00534","volume":"7","author":"LN Alberca","year":"2019","unstructured":"Alberca LN, Leal GG, Costa-Junior JA, Pereira-Junior VA, Lopes FR, Alves RS, et al. Ligand-based computational models combined with enzymatic assays for the discovery of new inhibitors for falcipain-2. Front Chem. 2019;7:38.","journal-title":"Front Chem"},{"issue":"2","key":"6015_CR31","first-page":"e02334","volume":"10","author":"R Sudhakar","year":"2022","unstructured":"Sudhakar R, Balamurugan V, Perumal Y. Identifying a new and effective antimalarial drug by testing existing, FDA-approved Selective Estrogen Receptor Modulators (SERMs) against drug-resistant strains of the malaria parasite. Microbiol Spectr. 2022;10(2):e02334-e2421.","journal-title":"Microbiol Spectr"},{"issue":"7","key":"6015_CR32","first-page":"1111","volume":"31","author":"C Irabuena","year":"2022","unstructured":"Irabuena C, Valdes MC, Gadea IJ, Monge ME. Chemical synthesis of the existing drug Nitazoxanide and its new analogs, followed by in vitro Antiplasmodial assessment. Med Chem Res. 2022;31(7):1111\u201322.","journal-title":"Med Chem Res"},{"issue":"2","key":"6015_CR33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/jmp.12034","volume":"42","author":"M Ichagichu","year":"2013","unstructured":"Ichagichu M, Olumide E, Kamau A, Wanjala C, Macharia A. Developing an optimized preclinical drug development system in Olive baboons (Papio Anubis) infected with the simian malaria parasite P. knowlesi, and using this system to test the antimalarial activity of the repositioned drug methotrexate. J Med Primatol. 2013;42(2):87\u201394.","journal-title":"J Med Primatol"},{"issue":"6","key":"6015_CR34","volume":"12","author":"H Matthews","year":"2017","unstructured":"Matthews H, Sharma A, O\u2019Neill PM. Synergistic antimalarial drug interactivity between emetine dihydrochloride hydrate and atovaquone. PLoS ONE. 2017;12(6):e0179675.","journal-title":"PLoS ONE"},{"issue":"11","key":"6015_CR35","first-page":"e00812","volume":"64","author":"P Panwar","year":"2020","unstructured":"Panwar P, Tripathi A, Tripathi M. Repurposing and optimizing the antiamoebic drug Dehydroemetine as a novel, fast-acting treatment for multi-drug resistant malaria (P. falciparum). Antimicrob Agents Chemother. 2020;64(11):e00812-e820.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"6015_CR36","doi-asserted-by":"crossref","first-page":"e13337","DOI":"10.1016\/j.heliyon.2023.e13337","volume":"9","author":"DO Ochora","year":"2023","unstructured":"Ochora DO, Ogutu FO, Nyakundi RO, Mwendwa SM, Ndombi RM, Keter DK. Target-similarity approach within a chemogenomics framework for identification of new antimalarial drug candidates against P. falciparum. Heliyon. 2023;9(2):e13337.","journal-title":"Heliyon"},{"key":"6015_CR37","first-page":"102857","volume":"100","author":"V Rajendran","year":"2025","unstructured":"Rajendran V, Sivaraja YR. Antimalarial drug development to address drug resistance in P. falciparum by repurposing Zinc Pyrithione (ZPT). Parasitol Int. 2025;100:102857.","journal-title":"Parasitol Int"},{"key":"6015_CR38","first-page":"115418","volume":"208","author":"S Shafi","year":"2023","unstructured":"Shafi S, Araya L, Das S. Drug repurposing study using in vitro and in vivo experiments: nitrofurantoin (NTF) in combination with Artemisinin (ART) for Artemisinin-resistant P. falciparum malaria. Biochem Pharmacol. 2023;208:115418.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"6015_CR39","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/jcb.29954","volume":"122","author":"K Verma","year":"2021","unstructured":"Verma K, Singh S, Chaudhary S. Computational drug reprofiling using a Polypharmacology approach to identify approved drugs with potential antimalarial activity. J Cell Biochem. 2021;122(10):1474\u201385.","journal-title":"J Cell Biochem"},{"issue":"7","key":"6015_CR40","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1021\/acsinfecdis.9b00015","volume":"5","author":"M Kumar","year":"2019","unstructured":"Kumar M, Bhartiya N, Sharma V. The development of new, highly potent, and multi-stage active compounds to combat drug-resistant malaria (P. falciparum) through derivatization of Astemizole. ACS Infect Dis. 2019;5(7):1160\u201371.","journal-title":"ACS Infect Dis"},{"issue":"5","key":"6015_CR41","first-page":"1732","volume":"10","author":"A Cox","year":"2024","unstructured":"Cox A, Poudel A, Zeeshan M, Poudel K, Poudel HR, Dhakal S, et al. Potent transmission-blocking efficacy of brusatol against malaria parasites. ACS Infect Dis. 2024;10(5):1732\u201341.","journal-title":"ACS Infect Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-06015-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-06015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-06015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:57:55Z","timestamp":1789599475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-06015-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6015"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-06015-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"331"}}